Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007
Characteristics of asthma patients responding to anti-IgE therapy Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Anti-IgE treatment: An alternative for severe allergic occupational asthma Source: Annual Congress 2012 - Asthma and COPD at work: what are the effects of exposure and risk factors? Year: 2012
Total and free IgE in evolution of severe asthma after omalizumab treatment Source: International Congress 2016 – Asthma management Year: 2016
Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005
The real world effectiveness and effect on adherence with inhaled asthma therapy of 1 year of Severe Asthma Monoclonal Antibody Treatment Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Clinical features of asthma complicated with eosinophilic otitis media and the effect of treatment with the anti-IgE monoclonal antibody omalizumub Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Therapeutic approach in allergic asthma: ASIT oposit to ICS Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2010
Management of severe allergic asthma in the UK: Which monoclonal antibody would you choose? Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002
How to evaluate a patient's response to anti-IgE Source: Eur Respir Rev 2007; 16: 78-84 Year: 2007
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Gender medicine and different prevalence in asthma by reports on anti-IgE (omalizumab) treatments Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007
Rhinophototherapy: a new tool for the treatment of allergic rhinitis? Source: ISSN=ISSN 1810-6838, ISBN=, page=174 Year: 2005
Omalizumab: therapeutic approach to asthma and comorbidities Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Effectiveness of anti-IgE and anti-IL-5 treatment in step 5 asthma patients. Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001